Claims

1. A crystalline for of4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol, which represents a sulfonate salt or a free base form.

2. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form I, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of 7.1° ± 0.2°, 12.9° ± 0.2°,15.4° ± 0.2°, 18.2° ± 0.2° and/or 21.2° ± 0.2°.

3. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form II, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of 7.8° ± 0.2°, 15.0° ± 0.2°, 17.6° ± 0.2°, 20.7° ± 0.2°and/or 23.3° ± 0.2°.

4. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form III, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of 10.2° ± 0.2°, 13.8° ± 0.2°, 15.1° ± 0.2°, 18.8° ± 0.2° and/or 19.9° ± 0.2°.

5. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form IV, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of 6.9° ± 0.2°, 12.6° ± 0.2°, 15.0° ± 0.2°, 15.7° ± 0.2° and/or 22.2° ± 0.2°.

6. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated

as Form V, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of6.9° ± 0.2°, 15.7° ± 0.2°, 17.5° ± 0.2°, 22.2° ± 0.2° and/or 25.4 ± 0.2°.

7. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)a mino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form VI, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) 6.7° ± 0.2°, 9.3° ± 0.2°, 16.1° ± 0.2°, 19.4° ± 0.2° and/or 25.0° ± 0.2°.

8. A crystalline form of 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol according to claim 1, designated as Form VII, characterized by a powder X-ray diffraction pattern having one, two, three, four or five peaks at a diffraction angle (2 theta) of 6.7° ± 0.2°, 9.9° ± 0.2°, 16.3° ± 0.2°, 19.1° ± 0.2°, and/or 24.3° ± 0.2.

9. A crystalline compound according to any of claims 1 to 8 for use as a medicament.

10. A crystalline compound according to any of claims 1 to 8 for use in the treatment and/or prevention of a parasitic infection, wherein the parasitic infection is preferably malaria, or a parasitic infection caused by plasmodium species.

11. A pharmaceutical composition comprising a therapeutically effective amount of at least one crystalline compound according to any of claims 1 to 8, wherein the pharmaceutical composition preferably comprises a therapeutically effective amount of second pharmacologically active substance, and wherein pharmacologically active substance is preferably an antimalarial.

12. A pharmaceutical composition according to claim 11 further comprising at least one additional compound selected from the group consisting of physiologi-

cally acceptable excipients, auxiliaries, adjuvants, diluents, carriers and/or additional pharmaceutically active substances other than the compounds according to any of claims 1 to 8.

13. Kit comprising a therapeutically effective amount of at least one crystalline compound according to any of claims 1 to 8 and/or at least one pharmaceutical composition as claimed in any of claims 11 or 12 and a therapeutically effective amount of at least one further pharmacologically active substance other than the crystalline compounds as claimed in any of claims 1 to 8, wherein the further is preferably an antimalarial agent.

14. Use of ~~A method for treating and/or preventing, comprising administering to a human in need of such a treatment a therapeutically effective amount of crystalline~~ a compound according to any of claims 1 to 8 for the preparation of a medicament.

15. Process for manufacturing of a crystalline modification according to any of claims 1 to 8.